Key facts
- Notable investors include LifeSpan Vision Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for PriveBio
- ·The full record, as it builds
Funding rounds
No funding rounds for PriveBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PriveBio
Operator of a precision medicine biotech company intended to develop novel medicines. The company develops therapeutics targeting metabolic dysfunction and fibro-inflammation in cardiorenal metabolic diseases, like heart failure, NASH/MASH, and chronic kidney diseases, by prosecuting validated targets from human proteogenomics data across very large human datasets, enabling clinicians to improve healthspan by helping their patients overcome fibro-inflammation in cardiorenal diseases and obesity in the post-GLP1 era.
- Sector
- Healthcare
- HQ
- New Castle, DE, United States
- Founded
- 2023
- Employees
- 2
- Website
- privebio.com/
- Ownership
- Privately Held (backing)
PriveBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PriveBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PriveBio in its N-PORT filings yet. We sweep new filings monthly.